Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (G030718N, 1S44216N)
Bijzonder Onderzoeksfonds UGent (-)
Stichting Alzheimer Onderzoek (S#16031)
VIB Technology Fund (-)
Belgian Rotary (Hope in Head Award)
Received: 18 April 2019
Accepted: 10 October 2019
First Online: 14 November 2019
Ethics approval and consent to participate
: All participants and/or their legal guardian provided written informed consent for participation in genetic studies. The study protocols were approved by the ethics committees of the Antwerp University Hospital and the participating neurological centers at the different hospitals of the BELNEU consortium and by the University of Antwerp (IRB approval UA A11-17 07/03/2011 and 17/50/526 2018.01.08). The experimental methods comply with the Declaration of Helsinki.
: All participants and/or their legal guardian provided written informed consent for anonymized usage of genetic data (IRB approval UA A11-17 07/03/2011).
: ADR and WDC have received travel reimbursement from Oxford Nanopore Technologies to speak at London Calling 2018, ASHG 2018, and AD/PD 2019. Oxford Nanopore Technologies has provided consumables free of charge for sequencing of the NA19240 reference genome. The other authors declare that they have no competing interests.